A pharmacotherapy of atrial fibrillation in subclinical thyrotoxicosis

Background. Pharmacological therapy of atrial fibrillation (AF) in subclinical dysfunction of the thyroid – is the most important problem of modern clinical medicine. The purpose of the study is to conduct a complex assessment of electrophysiological indicators of the heart and lipid profile in patients with subclinical thyrotoxicosis and paroxysmal AF during antiarrhythmic and thyrostatic therapy. Pharmacological therapy of atrial fibrillation (AF) in subclinical dysfunction of the thyroid is the most important problem of modern clinical medicine. Materials and methods. 126 patients with frequent paroxysms of AF with subclinical thyrotoxicosis were examined. All patients underwent ECG control, EP study, assessment of thyroid hormones level and lipid profile. Therapy included treatment with bisoprolol, sotalol, thiamazole and their combinations. Results. Electrophysiological predictors of AF in subclinical thyrotoxicosis were identified. It was found that euthyroid status does not reduce a number of spontaneous paroxysms of AF. High antiarrhythmic efficacy of combined use of bisoprolol with thiamazole and sotalol with thiamazole has been proven.